Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200434820> ?p ?o ?g. }
- W4200434820 endingPage "967" @default.
- W4200434820 startingPage "959" @default.
- W4200434820 abstract "Abstract Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the reduction of ischaemic events in patients with acute coronary syndrome (ACS). However, this comes at the expense of increased bleeding. A guided selection of P2Y12 inhibiting therapy has the potential to overcome this limitation. We aimed at evaluating the comparative safety and efficacy of guided vs. routine selection of potent P2Y12 inhibiting therapy in patients with ACS. Methods and results We performed a network meta-analysis of randomized controlled trials (RCTs) comparing different oral P2Y12 inhibitors currently recommended for the treatment of patients with ACS (clopidogrel, prasugrel, and ticagrelor). RCTs including a guided approach (i.e. platelet function or genetic testing) vs. standard selection of P2Y12 inhibitors among patients with ACS were also included. Incidence rate ratios (IRR) and associated 95% confidence intervals (CIs) were estimated. P-scores were used to estimate hierarchies of efficacy and safety. The primary efficacy endpoint was major adverse cardiovascular events (MACE) and the primary safety endpoint was all bleeding. A total of 61 898 patients from 15 RCTs were included. Clopidogrel was used as reference treatment. A guided approach was the only strategy associated with reduced MACE (IRR: 0.80, 95% CI: 0.65–0.98) without any significant trade-off in all bleeding (IRR: 1.22, 95% CI: 0.96–1.55). A guided approach and prasugrel were associated with reduced myocardial infarction. A guided approach, prasugrel, and ticagrelor were associated with reduced stent thrombosis. Ticagrelor was also associated with reduced total and cardiovascular mortality. Prasugrel was associated with increased major bleeding. Prasugrel and ticagrelor were associated with increased minor bleeding. The incidence of stroke did not differ between treatments. Conclusion In patients with an ACS, compared with routine selection of potent P2Y12 inhibiting therapy (prasugrel or ticagrelor), a guided selection of P2Y12 inhibiting therapy is associated with the most favourable balance between safety and efficacy. These findings support a broader adoption of guided approach for the selection of P2Y12 inhibiting therapy in patients with ACS. Study registration number This study is registered in PROSPERO (CRD42021258603). Key Question A guided selection of P2Y12 inhibiting therapy using platelet function or genetic testing improves outcomes among patients undergoing percutaneous coronary intervention. Nevertheless, the comparative safety and efficacy of a guided versus routine selection of potent P2Y12-inhibiting therapy in acute coronary syndrome has not been explored. Key Finding In a comprehensive network meta-analysis including the totality of available evidence and using clopidogrel as treatment reference, a guided approach was the only strategy associated with reduced major adverse cardiovascular events without any significant trade-off in bleeding. Prasugrel and ticagrelor increased bleeding and only ticagrelor reduced mortality. Take Home Message A guided selection of P2Y12-inhibiting therapy represents the strategy associated with the most favourable balance between safety and efficacy. These findings support a broader adoption of guided P2Y12 inhibiting therapy in patients with acute coronary syndrome." @default.
- W4200434820 created "2021-12-31" @default.
- W4200434820 creator A5002872853 @default.
- W4200434820 creator A5007026783 @default.
- W4200434820 creator A5007123733 @default.
- W4200434820 creator A5007593170 @default.
- W4200434820 creator A5016139987 @default.
- W4200434820 creator A5024294469 @default.
- W4200434820 creator A5028730426 @default.
- W4200434820 creator A5033100094 @default.
- W4200434820 creator A5033442682 @default.
- W4200434820 creator A5040418600 @default.
- W4200434820 creator A5070710719 @default.
- W4200434820 creator A5071922696 @default.
- W4200434820 creator A5078073832 @default.
- W4200434820 creator A5084791625 @default.
- W4200434820 creator A5087354675 @default.
- W4200434820 creator A5087550320 @default.
- W4200434820 date "2021-12-16" @default.
- W4200434820 modified "2023-10-16" @default.
- W4200434820 title "Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials" @default.
- W4200434820 cites W136622145 @default.
- W4200434820 cites W1986266381 @default.
- W4200434820 cites W1995777506 @default.
- W4200434820 cites W2098923148 @default.
- W4200434820 cites W2109577952 @default.
- W4200434820 cites W2111999709 @default.
- W4200434820 cites W2121205446 @default.
- W4200434820 cites W2140501627 @default.
- W4200434820 cites W2140776066 @default.
- W4200434820 cites W2161374186 @default.
- W4200434820 cites W2169387542 @default.
- W4200434820 cites W2509918966 @default.
- W4200434820 cites W2556925459 @default.
- W4200434820 cites W2570555403 @default.
- W4200434820 cites W2588681363 @default.
- W4200434820 cites W2603440970 @default.
- W4200434820 cites W2748517697 @default.
- W4200434820 cites W2754054868 @default.
- W4200434820 cites W2791656192 @default.
- W4200434820 cites W2902635828 @default.
- W4200434820 cites W2951424940 @default.
- W4200434820 cites W2971165578 @default.
- W4200434820 cites W2971992346 @default.
- W4200434820 cites W2988588188 @default.
- W4200434820 cites W2999143792 @default.
- W4200434820 cites W3000092873 @default.
- W4200434820 cites W3004480632 @default.
- W4200434820 cites W3019423044 @default.
- W4200434820 cites W3031115393 @default.
- W4200434820 cites W3080963011 @default.
- W4200434820 cites W3093863109 @default.
- W4200434820 cites W3104328056 @default.
- W4200434820 cites W3105723579 @default.
- W4200434820 cites W3136631970 @default.
- W4200434820 cites W3155255350 @default.
- W4200434820 cites W3156258501 @default.
- W4200434820 cites W3161729029 @default.
- W4200434820 cites W3162195278 @default.
- W4200434820 cites W3163043804 @default.
- W4200434820 cites W3163845177 @default.
- W4200434820 cites W3207761463 @default.
- W4200434820 cites W4211143229 @default.
- W4200434820 doi "https://doi.org/10.1093/eurheartj/ehab836" @default.
- W4200434820 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34918066" @default.
- W4200434820 hasPublicationYear "2021" @default.
- W4200434820 type Work @default.
- W4200434820 citedByCount "64" @default.
- W4200434820 countsByYear W42004348202022 @default.
- W4200434820 countsByYear W42004348202023 @default.
- W4200434820 crossrefType "journal-article" @default.
- W4200434820 hasAuthorship W4200434820A5002872853 @default.
- W4200434820 hasAuthorship W4200434820A5007026783 @default.
- W4200434820 hasAuthorship W4200434820A5007123733 @default.
- W4200434820 hasAuthorship W4200434820A5007593170 @default.
- W4200434820 hasAuthorship W4200434820A5016139987 @default.
- W4200434820 hasAuthorship W4200434820A5024294469 @default.
- W4200434820 hasAuthorship W4200434820A5028730426 @default.
- W4200434820 hasAuthorship W4200434820A5033100094 @default.
- W4200434820 hasAuthorship W4200434820A5033442682 @default.
- W4200434820 hasAuthorship W4200434820A5040418600 @default.
- W4200434820 hasAuthorship W4200434820A5070710719 @default.
- W4200434820 hasAuthorship W4200434820A5071922696 @default.
- W4200434820 hasAuthorship W4200434820A5078073832 @default.
- W4200434820 hasAuthorship W4200434820A5084791625 @default.
- W4200434820 hasAuthorship W4200434820A5087354675 @default.
- W4200434820 hasAuthorship W4200434820A5087550320 @default.
- W4200434820 hasBestOaLocation W42004348201 @default.
- W4200434820 hasConcept C126322002 @default.
- W4200434820 hasConcept C164705383 @default.
- W4200434820 hasConcept C168563851 @default.
- W4200434820 hasConcept C197934379 @default.
- W4200434820 hasConcept C203092338 @default.
- W4200434820 hasConcept C2777028646 @default.
- W4200434820 hasConcept C2777698277 @default.
- W4200434820 hasConcept C2777849778 @default.
- W4200434820 hasConcept C2780400711 @default.
- W4200434820 hasConcept C2780739214 @default.